Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Anavex Life Sciences Corp is a biotechnology business based in the US. Anavex Life Sciences shares (AVXL) are listed on the NASDAQ and all prices are listed in US Dollars. Anavex Life Sciences employs 20 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$12.45|
|52-week range||$3.65 - $31.50|
|50-day moving average||$22.54|
|200-day moving average||$14.60|
|Wall St. target price||$36.35|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.60|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||-49.35%|
|3 months (2021-05-04)||5.69%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-31.66%|
|Return on equity TTM||-56.58%|
|Market capitalisation||$1.3 billion|
TTM: trailing 12 months
There are currently 7.6 million Anavex Life Sciences shares held short by investors – that's known as Anavex Life Sciences's "short interest". This figure is 13.3% down from 8.8 million last month.
There are a few different ways that this level of interest in shorting Anavex Life Sciences shares can be evaluated.
Anavex Life Sciences's "short interest ratio" (SIR) is the quantity of Anavex Life Sciences shares currently shorted divided by the average quantity of Anavex Life Sciences shares traded daily (recently around 4.6 million). Anavex Life Sciences's SIR currently stands at 1.66. In other words for every 100,000 Anavex Life Sciences shares traded daily on the market, roughly 1660 shares are currently held short.
However Anavex Life Sciences's short interest can also be evaluated against the total number of Anavex Life Sciences shares, or, against the total number of tradable Anavex Life Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anavex Life Sciences's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Anavex Life Sciences shares in existence, roughly 110 shares are currently held short) or 0.1122% of the tradable shares (for every 100,000 tradable Anavex Life Sciences shares, roughly 112 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Anavex Life Sciences.
Find out more about how you can short Anavex Life Sciences stock.
We're not expecting Anavex Life Sciences to pay a dividend over the next 12 months.
Anavex Life Sciences's shares were split on a 1:4 basis on 6 October 2015. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anavex Life Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Anavex Life Sciences shares which in turn could have impacted Anavex Life Sciences's share price.
Over the last 12 months, Anavex Life Sciences's shares have ranged in value from as little as $3.654 up to $31.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anavex Life Sciences's is 0.6697. This would suggest that Anavex Life Sciences's shares are less volatile than average (for this exchange).
Anavex Life Sciences Corp. , a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York. .
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.